Propanc Biopharma Announces Plans To Start Phase 1b First-In-Human Study Of PRP In February 2027, Enrolling Up To 50 Patients With Advanced Solid Tumors In Australia; Says Ethics Submission Planned For November 2026
Share
Why It Matters
Propanc is planning to test a new cancer medicine in real people starting next year, with permission approval expected later this year. This shows the company is moving forward with its research plan, so you can watch if they hit these dates and what patients experience.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.